LOS ANGELES, CA - June 18, 2026 (NEWMEDIAWIRE) - Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on personalized, data-driven cardiovascular care powered by artificial intelligence, epigenetics and genetic insights. “Through its proprietary platform and expanding testing capabilities, the company is pursuing a future in which prevention becomes more accessible, scalable and actionable before life-threatening cardiac events occur,” reads a recent article. “The company’s vision reflects a broader shift taking place across the healthcare industry toward predictive and precision medicine. Cardio Diagnostics envisions a healthcare system where every patient receives individualized care informed by their unique molecular insights and where heart disease is no longer the world’s leading killer. Achieving that goal requires a combination of scientific expertise, advanced technology, scalable testing, and improved accessibility, all areas the company has identified as foundational pillars of its strategy.”

To view the full article, visit https://ibn.fm/gHSrl

About Cardio Diagnostics Holdings Inc.

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary artificial intelligence (“AI”)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law

View the original release on www.newmediawire.com

This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Cardio Diagnostics Holdings (CDIO) Aligns With Growing Shift Toward Predictive, Precision Medicine.